In Vitro and In Vivo activities of antibiotic PM181104

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5315-5319

  Mahajan, Girish ^a   Thomas, Becky ^a   Parab, Rajashri ^a   Patel, Zarine E ^a   Kuldharan, Sandip ^a   Yemparala, Vijayaphanikumar ^a   Mishra, Prabhu Dutt ^a   Ranadive, Prafull ^a   D'Souza, Lisette ^b   Pari, Koteppa ^a   Sivaramkrishnan, H ^a  

^a Piramal Enterprises Limited   (India)

^b NATIONAL INSTITUTE OF OCEANOGRAPHY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CYCLOPHOSPHAMIDE; FLUCONAZOLE; LINEZOLID; PM 181104; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATION; BODY WEIGHT; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; IN VIVO STUDY; KIDNEY INFECTION; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTICEMIA; STAPHYLOCOCCUS EPIDERMIDIS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACTINOBACTERIA; ANIMALS; ANTI-BACTERIAL AGENTS; AQUATIC ORGANISMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; ENTEROCOCCUS; FEMALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; SEPSIS; VANCOMYCIN RESISTANCE;

EID: 84885912318     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01059-13     Document Type: Article

References (15)

1. Menichetti F. 2005. Current and emerging serious Gram-positive infections. Clin. Microbiol. Infect. 11(Suppl 3):22-28.
2. Aeschlimann JR, Rybak MJ. 1998. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods. Antimicrob. Agents Chemother. 42:2188-2192.
3. Tenover FC, Weigel LM, Appelbaum PC, McDougal LK, Chaitram J, McAllister S, Clark N, Killgore G, O'Hara CM, Jevitt L, Patel JB, Bozdogan B. 2004. vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48:275-280.
4. Infectious Diseases Society of America. 2010. The 10 X '20 initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 15:1081-1083.
5. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
6. Mutnick AH, Enne V, Jones RN. 2003. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann. Pharmacother. 37: 769-774.
7. Skiest DJ. 2006. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol. 44:655-656.
8. Mayer AMS, Glaser KB, Cuevas C, Jacobs RS, Kem W, Little RD, McIntosh JM, Newman DJ, Potts BC, Shuster DE. 2010. The odyssey of marine pharmaceuticals: A current pipeline perspective. Trends Pharmacol. Sci. 31:255-265.
9. Mahajan GB, George SD, Ranadive PV, Mishra PDS, Eyyammadichiyil SS, Panshikar RM, Sawant SN, Krishna S, Sivakumar M, Pari K, Prabha D, D'Souza L, Naik CG, Patel ZE, Sivakumar M, Thomas B, Vishwakarma R. 2007. PM181104 and related antibacterial compounds, production, pharmaceutical compositions, and therapeutic use. International Patent Cooperation Treaty Application WO/2007/119201 A3.
10. Martín J, da Sousa ST, Crespo G, Palomo S, González I, Tormo JR, de la Cruz M, Anderson M, Hill RT, Vicente F, Genilloud O, Reyes F. 2013. Kocurin, the true structure of PM181104, an anti-methicillinresistant Staphylococcus aureus (MRSA) thiazolyl peptide from the marine-derived bacterium Kocuria palustris. Mar. Drugs 11:387-398.
11. Cañedo Hernández LM, Romero Millán F, Fernández Medarde A, Fernández Chimeno RI, Hidalgo Villar JC. 2012. Peptides as bioactive compounds. International Patent Cooperation Treaty Application WO/2012/062906.
12. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5, 5th ed. National Committee for Clinical Laboratory Standards, Wayne, PA.
13. Alder J, Li T, Yu D, Morton L, Silverman J, Zhang XX, Critchley I, Thorne G. 2003. Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection. Antimicrob. Agents Chemother. 47:3561-3566.
14. Mahajan GB, Shanbhag P, Sivaramakrishnan H. 2011. Mode of action of antibiotic PM181104 on bacteria, abstr registration no. 5SN3KNFPHL. 1st Global Forum on Bacterial Infections: Balancing Treatment Access and Antibiotic Resistance 2011. The Center for Disease Dynamics Economics & Policy, New Delhi, India.
15. Zhang C, Herath K, Jayasuriya H, Ondeyka JG, Zink DL, Occi J, Birdsall G, Venugopal J, Ushio M, Burgess B, Masurekar P, Barrett JF, Singh SB. 2009. Thiazomycins, thiazolyl peptide antibiotics from Amycolatopsis fastidiosa. J. Nat. Prod. 72:841-847.